Nova Satra Dx Pte. Ltd. is a Singapore-based molecular diagnostics startup led by Kane Black, Chief Executive & Co-Founder. Its lead product is a non-invasive blood-based diagnostic test for breast cancer. The test uses a University of Oxford–developed epigenetic platform that detects stable DNA-based chromosomal signatures (gene loops, chromosome domains, long-range chromosomal interactions) rather than unstable protein/RNA molecules. The breast cancer test has completed multi-centre Asian validation trials. The company intends to use funding for regulatory approvals and commercialization of the lead test. As part of recent commercial arrangements, a Genting subsidiary has obtained exclusive distribution rights in Malaysia.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2017